These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30581150)

  • 1. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target.
    Sciarrillo R; Terrana F; Comandatore A; Supadmanaba IGP; Wang B; Hassouni BE; Mantini G; Jansen G; Avan A; Carbone D; Diana P; Peters GJ; Morelli L; Cloos J; Assaraf YG; Giovannetti E
    Int J Biol Sci; 2024; 20(8):3173-3184. PubMed ID: 38904016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds.
    Cretu C; Agrawal AA; Cook A; Will CL; Fekkes P; Smith PG; Lührmann R; Larsen N; Buonamici S; Pena V
    Mol Cell; 2018 Apr; 70(2):265-273.e8. PubMed ID: 29656923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
    Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
    FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
    De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
    J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splicing factor SF3b as a target of the antitumor natural product pladienolide.
    Kotake Y; Sagane K; Owa T; Mimori-Kiyosue Y; Shimizu H; Uesugi M; Ishihama Y; Iwata M; Mizui Y
    Nat Chem Biol; 2007 Sep; 3(9):570-5. PubMed ID: 17643112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
    El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
    J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
    Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
    López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
    Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
    Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
    Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
    J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators.
    Aird D; Teng T; Huang CL; Pazolli E; Banka D; Cheung-Ong K; Eifert C; Furman C; Wu ZJ; Seiler M; Buonamici S; Fekkes P; Karr C; Palacino J; Park E; Smith PG; Yu L; Mizui Y; Warmuth M; Chicas A; Corson L; Zhu P
    Nat Commun; 2019 Jan; 10(1):137. PubMed ID: 30635584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
    Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
    Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
    Li Petri G; El Hassouni B; Sciarrillo R; Funel N; Mantini G; Zeeuw van der Laan EA; Cascioferro S; Avan A; Zucali PA; Zaffaroni N; Lagerweij T; Parrino B; Smid K; Deraco M; Granchi C; Braczko A; Smolenski RT; Matherly LH; Jansen G; Assaraf YG; Diana P; Cloos J; Peters GJ; Minutolo F; Giovannetti E
    Br J Cancer; 2020 Aug; 123(4):644-656. PubMed ID: 32493992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines.
    Jorge J; Petronilho S; Alves R; Coucelo M; Gonçalves AC; Nascimento Costa JM; Sarmento-Ribeiro AB
    Invest New Drugs; 2020 Apr; 38(2):369-377. PubMed ID: 31147807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 20. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
    Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
    Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.